News Image

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

Provided By GlobeNewswire

Last update: Sep 17, 2025

Recent advances in understanding venous malformation disease pathogenesis highlight the PI3K/AKT/mTOR pathway as a key driver of disease proliferation, spurring real-world off-label use of systemic rapamycin (sirolimus)

Read more at globenewswire.com

PALVELLA THERAPEUTICS INC

NASDAQ:PVLA (10/1/2025, 4:30:01 PM)

After market: 63.23 0 (0%)

63.23

+0.54 (+0.86%)



Find more stocks in the Stock Screener

Follow ChartMill for more